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included in the studies. To further assess the potential association 
between the polymorphism rs16901979 and the risk of prostate 
cancer in Afro-Caribbean men, we analyzed a larger sample of men 
living in Guadeloupe (French West Indies), a Caribbean population of 
predominantly West African ancestry.
MATERIALS AND METHODS
Study population
Subjects were recruited as part of a population-based case–control 
study in Guadeloupe (French West Indies), as previously described.14 
Briefly, consecutive patients who had histologically confirmed prostate 
cancer and attended public or private urological clinics participated 
in the study. Overall, the study population included 80% of new 
cases of prostate cancer in the Guadeloupe archipelago during the 
study period. Controls were recruited from the group of men who 
participated in a free systematic health screening program open to 
the general population during the same period. Each year, a random 
population sample was selected in accordance with the sex and age 
INTRODUCTION
Over the last few years, several genome-wide association studies 
have been performed on patients with prostate cancer and controls 
of Caucasian origin. These studies identified more than 70 loci or 
regions associated with the risk of prostate cancer.1 Notably, at least five 
different regions on the long arm of chromosome 8 at 8q24 have been 
implicated.2 These 8q24 loci were also studied in various populations of 
African descent, which have a higher incidence of prostate cancer and a 
higher associated mortality rate than Caucasian men. Among these loci, 
markers in region 2 of 8q24 were consistently found to be associated with 
prostate cancer susceptibility in men of African ancestry;3,4 in particular, 
the polymorphism rs16901979 is associated with a higher risk of prostate 
cancer in African-American men,5–11 Afro-Caribbean men (on Tobago 
island),12 and West African men (Nigerians).13 However, no association 
was reported between this single nucleotide polymorphism (SNP) and 
the risk of prostate cancer in men in Cameroon (Africa) or Jamaica 
(an Afro-Caribbean population).13 This discrepancy may be attributable 
to heterogeneity in African ancestry and/or the relatively small samples 
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Multiple regions of the genome have been associated with the risk of prostate cancer in Caucasians, particularly including several 
polymorphisms located at 8q24. Region 2 of 8q24 has been repeatedly found to be associated with the risk of prostate cancer 
among men of African descent, although one study performed in the Caribbean island of Jamaica did not report this finding. In this 
study, the single nucleotide polymorphism rs16901979, located in region 2 of 8q24, was genotyped in 498 cases of histologically 
confirmed prostate cancer and 541 controls from the French Caribbean islands of Guadeloupe, where the population is largely of 
African descent. The AA genotype and the A allele at rs16901979 were associated with elevated risks of prostate cancer (odds 
ratios [ORs] = 1.84, 95% confidence interval [95% CI] = 1.26–2.69, P = 0.002 and OR = 1.36, 95% CI = 1.13–1.64, P = 0.001, 
respectively). Following stratification of the patients by disease aggressiveness, as defined by the Gleason score, the pooled genotypes 
AC + AA were associated with a higher risk of a Gleason score ≥7 at diagnosis (OR = 1.79, 95% CI = 1.17–2.73, P = 0.007). In 
summary, the A allele at rs16901979 was associated with the risk of prostate cancer in the Caribbean population of Guadeloupe, 
confirming its involvement in populations of African descent. Moreover, our study provides the first evidence of an association 
between this variant and the risk of aggressive prostate cancer.
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distribution of the general population and invited to participate. The 
rate of participation exceeded 95% for both cases and controls. For both 
groups, inclusion criteria were as follows: no history of (or current) 
hormone treatment, including treatment with 5-α reductase inhibitors, 
and at least one parent born on a Caribbean island with a population 
recognized as being predominantly of African descent. Additional 
inclusion criteria for controls were normal findings upon digital rectal 
examination and a total plasma prostate-specific antigen concentration 
no higher than the 75th percentile of that of the appropriate age group of 
African-American men without clinical evidence of prostate cancer.15
Information was collected from both patients and controls 
concerning demographic characteristics, place of birth, parents’ place 
of birth, use of medication, and family history of prostate cancer. 
Participants were also asked to provide a blood sample. DNA was 
extracted from leucocytes using a standardized protocol. Eligible 
cases (n = 498) and controls (n = 537) had a DNA sample available at 
the time of genotyping. Their ages ranged from 40 to 94 years (Table 1). 
The clinical characteristics of the prostate cancer cases are also 
described in Table 1. The study was approved by the Guadeloupean 
Ethics Committee for studies involving human subjects and written 
informed consent was obtained from each participant.
Single nucleotide polymorphism genotyping
Genotyping was performed by the 5′ nuclease PCR method, using 
commercially available TaqMan® assays (Applied Biosystems, Foster 
City, CA, USA). Briefly, the final volume for PCR was 10 µl, which 
contained 10  ng DNA, 0.25 µl 40×  Assay Mix, and 5 µl TaqMan® 
Universal PCR master mix  (Applied Biosystems, Foster City, CA, 
USA). A first step at 92°C for 10 min was followed by 90 cycles of 92°C 
for 15 s and 60°C for 1 min. After PCR, end-point fluorescence was 
measured, and allelic discrimination was carried out using the  ABI 
7000 Sequence Detector (Applied Biosystems).
Statistical analyses
Genotypes were tested for consistency with the expected genotype 
frequencies under Hardy–Weinberg equilibrium in the control 
population. For the analysis of aggressiveness, the prostate cancer patients 
were stratified by the aggressiveness of their cancers, as defined by the 
Gleason score. Specifically, low aggressiveness was defined as a Gleason 
score <7 and high aggressiveness was defined as a Gleason score ≥7. 
A case-only analysis was performed. Odds ratios (ORs), as a measure 
of risk, and 95% confidence intervals (95% CIs) were estimated from 
logistic regression models with adjustment for age and Caribbean 
origin. P < 0.05 were considered as statistically significant. All statistical 
tests were two-tailed and were carried out using StatView version 5.0 
(SAS Institute Inc., Cary, NC, USA).
RESULTS AND DISCUSSION
We successfully determined the SNP rs16901979 genotype of 489 prostate 
cancer cases and 534 controls (Table 1). The genotype frequencies for 
healthy controls were in Hardy–Weinberg equilibrium. The frequency of 
the A allele in the control population (40%) was not different from the 
frequencies reported for African-Americans (42.5%5 and 42%6,10) and was 
statistically lower than the frequencies reported for West Africans (57% 
among Cameroonian controls and 50% among Nigerian controls).13
The AA genotype and the A allele at rs16901979 were associated with 
elevated risks of prostate cancer (OR = 1.84, 95% CI = 1.26–2.69, P = 0.002 
and OR = 1.36, 95% CI = 1.13–1.64, P = 0.001, respectively) (Table 2). 
This finding is in agreement with the study by Okobia et  al.12 of 
African-Caribbean men from Tobago, which found a significant 
association between this AA genotype and the risk of prostate cancer 
(OR = 1.57, 95% CI = 1.06–2.32, P = 0.02). In contrast, Murphy et al.13 
reported no association between this variant and the risk of prostate 
cancer in the population of the Caribbean island of Jamaica. The 
discrepancies between these three studies cannot be explained by 
the differences between the frequencies of the A allele in the three 
Caribbean populations: 42% among the controls from Guadeloupe 
(this study), 46% among those from Tobago,12 and 50% among the 
Jamaican controls.13 Thus, the A allele was statistically less frequent in 
controls from Guadeloupe than in controls from Tobago and Jamaica. 
By contrast, no difference was found between the controls from Tobago 
and Jamaica. Yet, despite the similar allele frequencies in Tobago and 
Jamaica, the significant association with prostate cancer risk in Tobago 
was not observed in Jamaica. The lack of an observed association in the 
population from Jamaica may be a consequence of the small numbers of 
cases (n = 96) and controls (n = 118) included the noted study.
Even if the frequency of the A allele at rs16901979 differs greatly 
according to the origin of the population, it appears that this variant 
is largely associated with the risk of prostate cancer. Indeed, it has 
now been implicated in populations of Caucasian,5,16–18 African,5–12 
and even Asian19,20 origin.
In this study, our comparison of prostate cancer cases with low 
and high aggressiveness  (Gleason score <7 vs ≥7) revealed that the 
pooled genotypes AC  +  AA were associated with a higher risk of 
a Gleason score  ≥7 at diagnosis  (OR  =  1.79, 95% CI  =  1.17–2.73, 
Table 1: Characteristics of the cases and controls
Cases (n=489) Controls (n=534)
Age, year
Median 66.3 60.0
Mean 66.5 60.5
Interquartile range 11.5 11.2
PSA (ng ml−1)
Median 8.7 0.8
Mean 34.9 1.1
Interquartile range 7.9 0.9
Origin, n (%)
French West Indies 
(Guadeloupe or Martinique)
473 (96.7) 490 (91.8)
Other Caribbean islands 
(Haiti or Dominica)
16 (3.3) 44 (8.2)
Clinical stage at diagnosisa, n (%)
T1c or T2 and N0 and M0 414 (91.6) -
T3 or T4, or N+ or M+ 38 (8.4) -
Gleason score at diagnosisb, n (%)
4–6 252 (53.6) -
7 174 (36.9) -
8–10 45 (9.5) -
aData on 37 patients were missing; bData on 18 patients were missing. 
PSA: prostate-specific antigen
Table 2: Associations between rs16901979 variants and the risk of 
prostate cancer
Variant Cases/controlsa ORb 95% CIc P
CC genotype 143/192 1 (reference)
AC genotype 239/253 1.34 1.00–1.81 0.05
AA genotype 107/89 1.84 1.26–2.69 0.002
C allele 0.54/0.60 1 (reference)
A allele 0.46/0.40 1.36 1.13–1.64 0.001
aNumber for the genotypes, frequency for the alleles; bOR adjusted for age and Caribbean 
origin; c95% CI. CI: confidence interval; OR: odds ratio
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P = 0.007) (Table 3). This is the first report of an association between 
the SNP rs16901979 and the risk of more aggressive prostate cancer 
in a population of African ancestry. However, another polymorphism 
in region 2 of 8q24, broad11934905, has similarly been shown 
to be associated with an increase in nonorgan confined disease 
and early biochemical recurrence after radical prostatectomy in 
African-American men.21 In addition, rs16901979 is associated 
with the risk of advanced disease in men of European16 and Asian22 
origin. However, other studies did not find any statistically significant 
difference between aggressive and nonaggressive cases in men of either 
European or African ancestry.3,7,23 Bensen et al.24 recently performed a 
large case-only study of 1536 candidate SNPs in 1066 African-American 
men and 1087 European men. They showed that the polymorphisms 
rs13254738 and rs1456305 in region 2 of 8q24 were associated with 
prostate cancer aggressiveness in African-American men and that 
rs6993569 in the same region was associated with prostate cancer 
aggressiveness in European men. They suggested that the apparent 
inconstancies between the two populations might reflect ethnic 
differences in the linkage disequilibrium structure of this region. 
Nevertheless, this study of a large series of African-American and 
Caucasian patients provided further evidence that region 2 of 8q24 is 
important in prostate cancer aggressiveness. In agreement with these 
results, linkage analyses performed by the International Consortium of 
Prostate Cancer Genetics found LOD scores (log10 of the ORs) over 3.0 
at 8q24 in families with multiple cases and more aggressive disease.25
CONCLUSIONS
We found that the A allele at rs16901979 was associated with the risk 
of prostate cancer in the population of the Caribbean archipelago of 
Guadeloupe. Our findings confirm the involvement of the A allele at 
rs16901979 in populations of African descent, irrespective of their 
locations or their migration stories (the United States, the Caribbean 
Islands, and West Africa). Furthermore, we report a positive association 
between this variant and the risk of aggressive prostate cancer.
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